Trial Profile
A multicenter, open-label, phase 2 study of Velcade (bortezomib) for injection in previously treated patients with stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Bronchiolo-alveolar adenocarcinoma
- Focus Therapeutic Use
- Acronyms PEAK
- 16 Feb 2011 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov.
- 16 Feb 2011 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov.
- 02 Nov 2006 Status change